GLP-1 Medications Explained: How They Work for Weight Loss

GLP-1 medications have changed the way physicians approach obesity and medical weight management. Medications such as semaglutide and tirzepatide can produce meaningful weight loss for appropriate patients, but their effects go well beyond simply making someone "eat less."

These medications interact with hormone pathways involved in appetite, fullness, digestion, and blood sugar regulation. For some patients, that can make it significantly easier to maintain the calorie reduction necessary for weight loss.

At the same time, GLP-1 medications are not appropriate for everyone, and successful treatment involves much more than writing a prescription. Medication selection, dosing, nutrition, muscle preservation, side-effect management, underlying medical conditions, and long-term weight maintenance all matter.

This article explains how GLP-1 medications work, what patients can realistically expect, and how they may fit into a comprehensive medical weight loss strategy.

What Are GLP-1 Medications?

GLP-1 stands for glucagon-like peptide-1, a hormone naturally released by the gastrointestinal tract after eating.

Among its many functions, GLP-1 helps communicate with areas of the brain involved in appetite and food intake. It also influences insulin and glucagon secretion and affects how quickly food moves through the stomach.

GLP-1 receptor agonist medications are designed to activate this same biological pathway.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is technically somewhat different: it activates both the GLP-1 receptor and the GIP receptor, another hormone pathway involved in metabolism and appetite regulation. Because both are widely used in modern medical weight management, people often informally group semaglutide and tirzepatide together as "GLP-1 medications."

Other medications in this broader category include liraglutide, an earlier GLP-1 medication used for both diabetes and weight management under different brand names and doses.

How Do GLP-1 Medications Help With Weight Loss?

There is no single mechanism responsible for their effects. Several processes work together.

1. They reduce appetite

One of the most important effects occurs in the brain.

GLP-1 receptors are present in areas involved in appetite regulation. Activating these pathways can reduce hunger and decrease calorie intake.

For many patients, this changes something that has made weight loss difficult for years: the biological drive to eat.

Rather than continuously fighting hunger while attempting to follow a lower-calorie diet, patients may feel satisfied with smaller portions and experience less frequent hunger between meals.

The FDA prescribing information for both semaglutide and tirzepatide specifically describes reductions in calorie intake related to appetite effects.

2. They can increase feelings of fullness

GLP-1 medications can also make a meal feel more satisfying.

A person who previously needed a large portion before feeling full may notice that considerably less food produces the same sensation.

This is one reason portion sizes can decrease relatively naturally during treatment.

Importantly, the objective should not be to suppress appetite so aggressively that a patient struggles to eat adequately. Good medical treatment aims for sustainable appetite control while maintaining sufficient nutrition.

3. They slow gastric emptying

Semaglutide and tirzepatide can delay gastric emptying, meaning food may leave the stomach more slowly.

This contributes to prolonged fullness after eating and is also one reason gastrointestinal symptoms may occur.

Tirzepatide's effect on gastric emptying is greatest following the initial dose and diminishes over time, according to current prescribing information.

This effect also has clinical implications beyond weight loss because delayed gastric emptying may affect how some oral medications are absorbed and is relevant when patients undergo procedures requiring anesthesia or deep sedation.

4. They affect insulin and glucagon

GLP-1-based medications also influence glucose metabolism.

They increase insulin secretion when blood glucose is elevated and reduce glucagon secretion. Tirzepatide has additionally been shown to improve insulin sensitivity.

These effects help explain why medications in this category were originally developed largely within diabetes care and why metabolic health often needs to be considered alongside body weight.

Patients interested in improving their overall metabolic health may also benefit from looking beyond the scale through a broader preventive care and health optimization approach.

Do GLP-1 Medications Actually Burn Fat?

Not exactly.

GLP-1 medications are sometimes described online as "fat-burning injections," but that is an oversimplification.

Their primary weight-loss effect is not that they dramatically accelerate metabolism or directly dissolve fat. Rather, they modify biological signals involved in appetite and food intake, making sustained calorie reduction more achievable.

As body weight decreases, both fat mass and some lean tissue can be lost. FDA prescribing information for semaglutide and tirzepatide notes that weight reduction involves greater fat-mass loss than lean-mass loss.

That does not mean muscle preservation can be ignored.

Adequate protein intake, appropriate resistance exercise, and avoidance of unnecessarily rapid weight loss are important parts of a well-designed medical weight loss plan.

Which GLP-1 Medications Are Used for Weight Loss?

Several medications affecting the GLP-1 pathway have FDA-approved weight-management indications.

Semaglutide

Semaglutide is a GLP-1 receptor agonist.

For weight management, the best-known brand is Wegovy. Semaglutide is also sold under other brand names and doses for different medical indications.

That distinction matters. The fact that two medications contain the same active ingredient does not mean their FDA indications, dosing schedules, or prescribing instructions are identical.

Tirzepatide

Tirzepatide activates both GLP-1 and GIP receptors and is therefore described as a dual GIP/GLP-1 receptor agonist.

Its FDA-approved weight-management brand is Zepbound. Tirzepatide is also marketed as Mounjaro for type 2 diabetes.

Liraglutide

Liraglutide is an earlier GLP-1 receptor agonist. The weight-management formulation is marketed as Saxenda and is administered daily rather than weekly.

The National Institute of Diabetes and Digestive and Kidney Diseases lists liraglutide, semaglutide, and tirzepatide among FDA-approved medications for long-term weight management.

Which option is appropriate depends on the patient's medical history, goals, medication tolerance, insurance coverage, availability, and other clinical considerations.

How Much Weight Can You Lose With GLP-1 Medications?

There is no single percentage that applies to everyone.

Clinical trials have demonstrated substantial average weight reductions with newer GLP-1-based treatments, particularly semaglutide and tirzepatide, but individual results can vary considerably.

For example, the STEP 1 trial demonstrated clinically meaningful weight reduction with semaglutide in adults with overweight or obesity, while the SURMOUNT-1 trial showed substantial and sustained weight reduction across studied tirzepatide doses.

More recent head-to-head research has also demonstrated significant weight reduction with both medications. In a 72-week trial among adults with obesity without diabetes, tirzepatide produced greater average weight reduction than semaglutide at the maximum tolerated doses used in the study.

These numbers are useful for understanding what medications can accomplish across large groups, but they should not become an individual patient's required target.

Response varies because body weight is influenced by many factors, including:

• genetics

• baseline body composition

• calorie intake

• physical activity

• sleep

• medications

• metabolic health

• hormonal factors

• medical conditions

• medication dose and tolerance

• duration of treatment

The more useful question is usually not, "How much weight should this drug make me lose?"

It is, "Is this treatment improving my health in a safe, sustainable way?"

Who May Be a Candidate for GLP-1 Weight Loss Treatment?

For many FDA-approved chronic weight-management medications, adult eligibility generally includes people with obesity or people with overweight plus at least one weight-related medical condition. Individual products have their own specific labeling and indications.

Potential weight-related conditions may include issues such as:

• hypertension

• abnormal cholesterol

• type 2 diabetes

• obstructive sleep apnea

• cardiovascular disease

BMI can be useful as a screening tool, but it does not tell the entire story.

Two patients with the same BMI can have very different body compositions, metabolic risks, medical histories, medications, lifestyles, and treatment goals.

That is why medication decisions should ideally follow an individualized evaluation rather than being based solely on a number on the scale.

What Should Be Evaluated Before Starting a GLP-1 Medication?

Before prescribing a GLP-1-based medication, I believe it is important to understand why the patient is struggling with weight in the first place.

The medical evaluation may include a review of:

• previous weight-loss attempts

• current medications and supplements

• eating patterns

• physical activity

• sleep

• alcohol intake

• gastrointestinal history

• gallbladder history

• pancreatic history

• personal and family medical history

• diabetes and metabolic risk

• reproductive plans

• thyroid history

• current symptoms and health goals

Laboratory testing may also be appropriate depending on the individual patient.

For example, glucose or hemoglobin A1C, lipid testing, kidney and liver markers, and other laboratory tests may provide useful information when evaluating overall metabolic health.

This is one of the reasons I view GLP-1 treatment as medical weight management, rather than simply prescription-based weight loss.

What Are the Most Common GLP-1 Side Effects?

The most common side effects are gastrointestinal.

Depending on the medication, these can include:

• nausea

• vomiting

• diarrhea

• constipation

• abdominal discomfort

• indigestion or reflux

• decreased appetite

These symptoms often occur during treatment initiation or dose escalation.

Higher doses are not automatically better. A dose that produces excellent appetite control but causes persistent nausea, inadequate food intake, dehydration, or significant constipation may not be the right dose for that patient.

A thoughtful dosing plan considers both response and tolerability.

Current FDA labeling for semaglutide and tirzepatide identifies gastrointestinal effects among their most frequently reported adverse reactions.

What Are the More Serious Risks?

Although most patients will not experience serious complications, GLP-1-based medications require appropriate medical screening and monitoring.

Potential concerns can include pancreatitis, gallbladder disease, severe gastrointestinal reactions, dehydration and associated kidney injury, hypersensitivity reactions, and hypoglycemia when used with certain diabetes medications.

Semaglutide and tirzepatide also carry boxed warnings regarding thyroid C-cell tumors based on animal data. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Whether these medications cause thyroid C-cell tumors in humans has not been established.

Weight-loss medications should not be used during pregnancy. Medication-specific guidance should also be reviewed for patients planning pregnancy.

Tirzepatide deserves another specific consideration: because it delays gastric emptying, its prescribing information contains guidance concerning oral hormonal contraceptives during treatment initiation and dose escalation.

Patients undergoing surgery or procedures requiring anesthesia should also tell their surgical and anesthesia teams that they take a GLP-1 or GIP/GLP-1 medication because delayed gastric emptying can be clinically relevant.

These are exactly the types of issues that make physician supervision important.

Do You Still Need to Change Your Diet While Taking a GLP-1 Medication?

Yes.

Medication can make nutritional changes considerably easier, but it does not make nutrition irrelevant.

In fact, because appetite may be significantly reduced, food quality can become even more important.

If a patient is eating substantially less food, there is less room for nutritionally poor choices.

A medical weight loss diet should generally prioritize foods that provide adequate protein, fiber, vitamins, minerals, and other essential nutrients while fitting the patient's calorie needs and medical history.

Helpful priorities often include:

• adequate protein

• vegetables and fruit

• high-fiber foods

• minimally processed foods

• appropriate portion sizes

• sufficient fluids

• nutrient-dense foods rather than simply eating as little as possible

For more information on the nutritional and lifestyle side of metabolic health, visit the Healthy Living & Nutrition Resource Center.

Why Resistance Training Matters During GLP-1 Weight Loss

When body weight falls, some lean mass is typically lost along with fat.

For that reason, resistance training should not be viewed only as a way to burn additional calories.

Its more important role during weight loss may be helping preserve strength, function, and metabolically valuable lean tissue.

Depending on a patient's health and physical abilities, a weight loss program may therefore include some combination of:

• resistance training

• regular walking

• cardiovascular exercise

• adequate protein intake

• sufficient recovery and sleep

The goal is not simply to create the lowest possible number on the scale.

The goal is to improve body composition, metabolic health, physical function, and long-term health.

How Quickly Should GLP-1 Doses Be Increased?

Most GLP-1-based weight-loss medications are intentionally started at a lower dose and increased gradually.

This is primarily done to improve gastrointestinal tolerability.

A common misconception is that patients should reach the highest dose as quickly as possible. In practice, dose selection should be individualized according to the specific medication's prescribing information, the patient's response, and tolerability.

The best dose is not necessarily the highest available dose.

It is the dose that provides an appropriate clinical benefit while remaining reasonably tolerable.

Patients should not independently change their dosing schedule or increase their dose because weight loss has temporarily slowed.

What Happens When You Stop a GLP-1 Medication?

This is one of the most important conversations to have before treatment begins.

Obesity tends to behave like a chronic condition rather than a problem that is permanently eliminated after reaching a particular number on the scale.

Clinical withdrawal studies support this concept.

In an extension of a semaglutide trial, participants regained a substantial portion of their previous weight loss after the medication was discontinued. Tirzepatide withdrawal studies have similarly demonstrated significant weight regain in many participants who stopped treatment.

This does not necessarily mean every patient must remain on the same medication indefinitely.

It does mean that there should be a maintenance strategy.

That strategy may involve continued pharmacologic treatment, nutrition changes, resistance exercise, behavioral changes, adjustment of medications that influence weight, ongoing monitoring, or some combination of these approaches.

The maintenance plan deserves just as much attention as the initial weight-loss plan.

Are GLP-1 Medications a Shortcut?

I don't think "shortcut" is a particularly useful way to think about these medications.

Body-weight regulation involves complex biological systems controlling hunger, satiety, metabolism, energy expenditure, and food intake.

Medication can modify some of those systems.

Someone who is able to maintain healthier eating patterns because medication has reduced excessive hunger is still making meaningful changes to their health.

At the same time, medication should not become a substitute for addressing other important factors such as nutrition, exercise, sleep, metabolic disease, medications that contribute to weight gain, or unhealthy eating patterns.

The strongest approach combines the biological benefits of medication with a sustainable long-term health strategy.

What Does Physician-Guided GLP-1 Weight Loss Look Like?

A well-designed medical weight loss program should involve more than providing medication.

I consider several questions throughout treatment:

Is the medication working?

Weight is one measurement, but waist circumference, appetite, food intake, blood pressure, blood sugar, laboratory markers, energy, and physical function may provide additional information.

Is the patient tolerating treatment?

Persistent nausea, vomiting, constipation, reflux, dehydration, or inability to eat adequately should not simply be ignored in pursuit of faster weight loss.

Is nutrition adequate?

Patients still need protein, fiber, micronutrients, and sufficient overall nutrition even when appetite is reduced.

Are we protecting muscle and function?

Resistance exercise, protein intake, and an appropriate rate of weight loss deserve attention.

Are there medical factors working against the patient's progress?

Weight management may require addressing sleep, medications, metabolic disease, hormonal concerns, pain limiting activity, or other health issues.

What is the long-term maintenance strategy?

Successful weight management should be designed around what happens months and years from now—not merely what the scale says next week.

Patients who want to explore whether medication may be appropriate can learn more about my GLP-1 Medical Weight Loss program.

GLP-1 Treatment Should Be Personalized

Two patients can use the same medication and have completely different experiences.

One may experience dramatic appetite reduction at a relatively low dose. Another may require gradual dose escalation before noticing much change. One may experience almost no gastrointestinal symptoms, while another may need significant adjustments because of nausea or constipation.

Patients may also have very different priorities.

One person's goal may be reducing diabetes risk. Another may want to improve mobility. Someone else may be trying to lower blood pressure, improve sleep apnea, prepare for joint surgery, or simply make maintaining healthier eating habits more manageable.

That is why medical weight loss should be personalized around the patient, not simply around the medication.

For patients who prefer broader ongoing physician involvement rather than treatment centered on a single condition, information about Ask Dr. Hu's concierge medicine membership is also available.

Final Thoughts

GLP-1 medications can be powerful tools for weight management because they affect several biological pathways involved in appetite, fullness, digestion, and metabolic regulation.

But the medication itself is only one part of successful treatment.

The most effective long-term strategy considers:

• why weight gain occurred

• whether medication is medically appropriate

• how the patient tolerates treatment

• nutritional quality

• preservation of muscle

• physical activity

• metabolic health

• realistic weight-loss goals

• and what will happen after the initial weight-loss phase

For the right patient, GLP-1-based therapy can make sustainable weight management considerably more achievable. The goal should not simply be rapid weight loss. It should be better health with a plan that can be maintained over time.

To learn more about medical weight management in Arizona, visit the Medical Weight Loss Resource Center or review the GLP-1 Medical Weight Loss program.

If you would like to discuss your individual health history and whether medical weight management may be appropriate, you can contact Ask Dr. Hu.

Medical Accuracy and Evidence Standards

This article was written and medically reviewed by YiQiu Hu, NMD, an Arizona-licensed naturopathic physician and founder of Ask Dr. Hu.

Clinical information on this page is based on current prescribing information, established medical literature, and guidance from recognized medical and government sources. Medication indications and safety information can change as new research and regulatory updates become available.

Key sources used in reviewing this article include:

• U.S. Food and Drug Administration — Wegovy (semaglutide) Prescribing Information

• U.S. Food and Drug Administration — Zepbound (tirzepatide) Prescribing Information

• National Institute of Diabetes and Digestive and Kidney Diseases — Prescription Medications to Treat Overweight & Obesity

• STEP 1 Trial — Semaglutide in Adults With Overweight or Obesity

• SURMOUNT-1 Trial — Tirzepatide for the Treatment of Obesity

• STEP 1 Extension — Weight Regain After Semaglutide Withdrawal

• SURMOUNT-4 Trial — Tirzepatide and Long-Term Weight Maintenance

The purpose of these references is to provide transparency regarding the scientific and regulatory sources used to support the medical information presented on this page.

About the Author

YiQiu Hu, NMD is an Arizona-licensed naturopathic physician and founder of Ask Dr. Hu. His clinical work focuses on individualized, physician-led care with interests that include preventive healthcare, health optimization, medical weight management, hormone care, integrative pain management, and complex health concerns.

Through Ask Dr. Hu, Dr. Hu provides patients throughout Arizona with longer appointments, direct physician access, individualized treatment planning, and an emphasis on practical, evidence-informed healthcare.

Learn more about Dr. Hu and Ask Dr. Hu.

Medical Disclaimer

This article is intended for general educational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment. Prescription weight-management medications have potential risks, contraindications, side effects, and drug interactions. Medication decisions should be made with a qualified healthcare professional who can review your individual medical history, medications, laboratory findings, and treatment goals.